论文部分内容阅读
拉帕替尼(lapatinib,1),化学名为N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[[2-(甲磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺,是葛兰素史克公司研发的酪氨酸激酶抑制剂,其二(对甲苯磺酸盐)一水合物于2007年3月在美国上市,商品名Tykerb,临床用于治疗2型人表皮生长因子受体过度表达引起的晚期或转移性乳腺癌。
Lapatinib (1) with chemical name N- [3-chloro-4- (3-fluorobenzyloxy) phenyl] -6- [5- [[2- (methylsulfonyl) Amino] methyl] -2-furyl] -4-quinazolinamine, a tyrosine kinase inhibitor developed by GlaxoSmithKline, and its bis (p-toluenesulfonate) monohydrate in 2007 Marketed in the United States in March, under the trade name Tykerb, is clinically used to treat advanced or metastatic breast cancer caused by overexpression of type 2 human epidermal growth factor receptor.